Chronic Hyperammonemia: Ravicti (Glycerol Phenylbutyrate)
Customize your policy alerts
Sign up for Molina Healthcare Policy C7041-A alerts
Get alerted when Policy C7041-A changes without checking for updates manually.
Monitor payer policy activity
Prior authorization and continued coverage of oral Ravicti for chronic hyperammonemia caused by a qualifying urea cycle disorder, subject to diagnostic confirmation, required prior therapies, specialist involvement, and evidence of treatment response and adherence.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.